Eli Lilly & Co(CH:LLY)
CHF 1,190.00-30.00 (-2.46%)
CH:LLY
Eli Lilly & Co stock drug pipeline
CHF 1,190.00
At close:-30.00 (-2.46%)
Eli Lilly & Co (LLY) Drug Pipeline
4 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Eli Lilly And Company (CH:LLY) have in its pipeline
Eli Lilly & Co CH:LLY is currently developing the following drugs: Imlunestrant, Omeprazole, Ly3484356, Ly4247147, Ly3819469, Lepodisiran, Ly3841136, Eloralintide, Ly3873862, Cyp450 Drug Cocktail, Ly4167586, Tirzepatide, Eloralintide And Tirzepatide, Tirzepatide, Ly3841136, Eloralintide, Eloralintide And Tirzepatide, Midazolam, Ly5625573, [¹⁴C]-Ly4515100 Oral Solution, Ly4515100 Tablet, [¹⁴C]-Ly4515100 Iv, Florbetapir F18, Florbetaben F 18, Ly4560736, Donanemab, Ly3002813, Vepugratinib, Ly3866288, Selpercatinib, Tirzepatide, Oxaliplatin, Cetuximab, 5-Fluorouracil, Olomorasib, Leucovorin/Levofolinate Calcium, Ly3537982, Ly4329090, Combined Oral Contraceptive, Eloralintide, Ly3841136, Tirzepatide, Acetaminophen, Ly5625575, Abemaciclib Tablet, Abemaciclib Oral Granules, Orforglipron, Ly3502970, Florbetapir F18, Ly4405094, Florbetaben F 18, Clazakizumab, Brenipatide, Ly3537031, Eloralintide, Macupatide, Ly3532226, Midazolam, Ly4355756, Standard Of Care, Ly3537031, Brenipatide, Acetaminophen, Eloralintide, Ly3841136, Ly4268989, Eloralintide, Ly3841136, Ly4178256, Dulaglutide, Orforglipron, Ly3502970, High-Fat Meal, Tersolisib, Low-Fat Meal, Ly4064809, Ly4174794, Ly4065967. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

